Obesity Medicine Board Review Questions

Obesity Medicine Board Review QuestionsObesity Medicine Board Review QuestionsObesity Medicine Board Review Questions
  • Home
  • Blog
  • Online QBank
  • Shop
  • Bio
  • Contact Me
  • Book Updates
  • More
    • Home
    • Blog
    • Online QBank
    • Shop
    • Bio
    • Contact Me
    • Book Updates

Obesity Medicine Board Review Questions

Obesity Medicine Board Review QuestionsObesity Medicine Board Review QuestionsObesity Medicine Board Review Questions
  • Home
  • Blog
  • Online QBank
  • Shop
  • Bio
  • Contact Me
  • Book Updates

Second Edition (2022) Book Updates

**Please note errata that affects all books demarcated by dual astricks**


The great thing about obesity medicine is the new advances in treatment options! However, this can make books outdated before the next edition. Therefore, I have added updates and the questions affected below.


NOTE: If you purchased the second edition book from this site or Amazon after 8/2/2022, these updates have already been made in the books themselves, except for those demarcated by **, which applies to all books.

See If Your Book is Affected

Obesity Medicine: 185 Board Review Questions

Update topics, followed by questions affected

**Errata: (Affects all): Correction to Question Stem**

81

Inaccurate conversions: The weight in kg for the patient should be 117 kg (NOT 136) and the height should be 178 cm (NOT 170). The chart itself is accurate, and per the lead-in, is recommended to be used to obtain correct answer with given height in inches (70 inches = 5'10") and weight in pounds.

Phentermine/Topiramate ER (Qsymia®)

91, 122

This medication is now approved for those aged 12 and older (previously only approved for adults).

Setmelanotide

2, 21, 151

Setmelanotide gained a new FDA indication to treat those with Bardet-Biedl Syndrome.

Post-Gastric Bypass Hypoglycemia

124, 137

The term hyperinsulinemic hypoglycmia was changed to post-gastric bypass hypoglycemia (PGBH) to be more consistent with current terminology. A note on late dumping syndrome was also added to the explanation, "Late dumping syndrome may present similarly in timeframe to PGBH but would not cause neuroglycopenia and would respond to dietary changes alone." See new table.

GLP-1 Induced Pancreatitis

62, 108

Although listed as a potential concern on the drug insert, meta-analysis has shown no increased risk of pancreatitis or pancreatic cancer with GLP-1 use. 

Tirzepatide

99

Tirzepatide (Mounjaro®) was recently approved for diabetes and is expected to be soon approved for obesity. The original version stated it was expected to be approved for diabetes soon- well, we made it!

-Triple G (GLP-1, glucagon, and gastric inhibitory peptide) was added to the list of medications actively being studied for weight loss.


Obesity Medicine: Practice Tests

Same update description above, followed by questions affected

Phentermine/Topiramate ER (Qsymia®)

46

Setmelanotide

46, 81, 187

**Errata: (Affects all): Correction to Question Stem**

71

 A company produces a synthetic high-potency hormone  that suppresses glucagon production and INCREASES satiety 

Post-Gastric Bypass Hypoglycemia

4, 234

**Errata: (Affects all): Correction to Question Stem**

218

Exogenous leptin is injected into a test subject. This hormone is found to STIMULATE which of the following pathways? 

GLP-1 Induced Pancreatitis

222

Note: The answer for 222 has been modified. See updated version.

  • Privacy Policy
  • Terms and Conditions

Obesity Medicine Board Review Questions

Copyright © 2025 Obesity Medicine Board Review Questions, LLC - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept